Exogenous progestogen and estrogen implicated in birth defects.

Area of Science:

• Teratology
• Reproductive Toxicology
• Pediatric Health

Background:

• Exogenous female sex hormones have been historically prescribed during pregnancy.
• Potential teratogenic effects of these hormones require thorough investigation.
• Understanding the risks associated with prenatal hormone exposure is crucial for public health.

Purpose of the Study:

• To investigate the potential teratogenicity of exogenous female sex hormones.
• To quantify the association between maternal hormonal exposure and specific infant malformations.
• To evaluate risks for VACTERL anomalies, congenital heart lesions, and neurological disorders.

Main Methods:

• A five-year study incorporating three case-control studies and one cohort study.
• Case-control analysis comparing infants with major anomalies to controls regarding maternal hormonal exposure.
• Prospective study assessing malformations in relation to hormonal exposure rates over time.

Main Results:

• A relative risk (RR) of 8.41 was found for maternal hormonal exposure in infants with VACTERL anomalies (P < .001).
• Two case-control studies reported RRs of 5.58 (P = .017) and 3.35 (P < .001) for congenital heart lesions.
• A prospective study indicated increased risks for major malformations (RR = 2.75), heart anomalies (RR = 6), and neural tube defects.

Conclusions:

• Maternal exposure to exogenous female sex hormones is associated with an increased risk of major infant malformations, including VACTERL anomalies and congenital heart defects.
• The findings suggest a teratogenic potential of these hormones, necessitating caution in their use during pregnancy.
• Further research is warranted to elucidate specific hormonal mechanisms and refine risk assessments.